Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

(2022) Yuichiro Doki et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

(2022) Zi-Xian Wang et al.   CANCER CELL

Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China

(2022) Yang Yang et al.   DISEASES OF THE ESOPHAGUS

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

(2022) Zhihao Lu et al.   BMJ-British Medical Journal

Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world

(2022) Pei Zhang et al.   Annals of Translational Medicine

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single Arm Phase II Feasibility Trial (PERFECT)

(2021) Tom van den Ende et al.   CLINICAL CANCER RESEARCH

Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

(2021) Wei Cao et al.   CHINESE MEDICAL JOURNAL

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

(2021) Ben M. Eyck et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

(2021) Ronan J. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma

(2021) Wencheng Zhang et al.   ONCOLOGIST

Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma

(2021) Tzu-Hui Pao et al.   PLoS One

Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma

(2021) Xianbin Wu et al.   Cancer Cell International

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

(2021) Huiyan Luo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study)

(2021) Maarten C. C. M. Hulshof et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

(2021) Jong-Mu Sun et al.   LANCET

Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

(2021) Mao-Hui Yan et al.   World Journal of Gastrointestinal Oncology

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

(2020) M. Moehler et al.   ANNALS OF ONCOLOGY

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

(2020) Lihong Peng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)

(2020) Shun Yamamoto et al.   Future Oncology

Peripheral blood cell count ratios are predictive biomarkers of clinical response and prognosis for non‐surgical esophageal squamous cell carcinoma patients treated with radiotherapy

(2020) Xiaohui Zhi et al.   JOURNAL OF CLINICAL LABORATORY ANALYSIS

Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)

(2020) Chengqiang Li et al.   EUROPEAN JOURNAL OF CANCER

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody

(2019) Xi Wang et al.   Thoracic Cancer

Neutrophil–to–lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

(2019) JHE-CYUAN GUO et al.   ANTICANCER RESEARCH

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial

(2018) Hong Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

(2018) K Muro et al.   ANNALS OF ONCOLOGY

Épidémiologie des tumeurs MSI : fréquence des tumeurs MSI en fonction de la localisation du cancer et de son stade

(2018) Raphaël Colle et al.   BULLETIN DU CANCER

Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

(2016) Thomas W. Rice et al.   DISEASES OF THE ESOPHAGUS

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

(2015) Joel Shapiro et al.   LANCET ONCOLOGY

Epidemiology of Esophageal Cancer in Japan and China

(2013) Yingsong Lin et al.   JOURNAL OF EPIDEMIOLOGY